As the year gets underway, analysts and biotech executives highlight cell therapy’s pivot from oncology to autoimmune ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

A new weight loss biotech launched with $410 million and three assets from China. Roche's Chugai penned a deal to develop ...

A new study reveals the rising burden of liver cancer, highlighting the significant impact of metabolic risk factors like ...

Researchers found that an increase in PM2.5 levels by 16.2 micrograms per cubic meter during preconception was linked to a ...

In a study of more than 5,000 mothers and their children, exposure to air pollution during the three months before pregnancy predicted higher child body mass index (BMI) and related obesity risk ...

Data from Hengrui’s Phase II trial for its GLP-1/GIP product demonstrated a statistically significant mean weight loss of ...

Eli Lilly (LLY 1.45%) began a roll in late 2020 that lasted almost four years. During that time, it became the world's ...

Liver cancer is a leading cause of cancer-related deaths worldwide, with distinct geographic patterns in its incidence.

Financing was co-led by Forbion and General Atlantic, with participants such as RA Capital Management, OrbiMed, and Lilly ...